ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Amgen is again making cuts to its research unit, this time shedding about 200 R&D jobs, primarily at labs in California. In March, about 500 employees at Amgen’s Thousand Oaks, Calif., headquarters were affected by a decision to shift certain research activities and support services to other sites. As part of the earlier move, research was concentrated at the firm’s facilities in San Francisco and Cambridge, Mass., threatening some 100 jobs in its discovery and translational research operations. In a statement Amgen says the new round of cuts is driven by a need to be “increasingly efficient in our operational discipline.” In a separate move, but one also aimed at efficiency, Genentech is shedding 130 jobs at its Vacaville, Calif., manufacturing facility. The company points to changing demand for injectable medications.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X